MAP2K7 and lung giant cell carcinoma: However, in line with clinical needs, Xi et al. [16] have demonstrated the potential benefits of targeted therapy for giant cell carcinoma of the lung based on molecular profiling, suggesting a possible survival benefit from MEK inhibitors, CDK4/6 inhibitors, and TP53 inhibitors.